Interactive FIX Dose Calculator
Enter values and click Calculate dose.
Estimate Factor IX (FIX) dose in international units (IU) for Hemophilia B using body weight, current FIX activity, target FIX activity, and expected in vivo recovery. This page also includes a detailed dosing guide for bleeding episodes, procedures, and follow-up planning.
Enter values and click Calculate dose.
Factor IX dose calculation is the process of estimating how many IU of FIX concentrate are needed to raise a patient’s plasma FIX activity from a measured current level to a planned therapeutic target. This is central to treatment in Hemophilia B for spontaneous bleeding, trauma, procedures, and surgery.
Most practical dosing starts with a weight-based bolus model. A predicted rise in FIX activity is calculated from the dose and expected recovery. Because recovery and half-life vary between patients and products, clinicians frequently confirm response with post-infusion levels and then refine the regimen.
The standard bedside approach is:
Dose (IU) = Body Weight (kg) × (Target FIX% − Current FIX%) ÷ Recovery
| Clinical situation | Typical initial target FIX activity | General concept |
|---|---|---|
| Minor mucosal/joint bleed | ~20–40% | Early treatment may reduce total dose need and duration. |
| Moderate soft tissue or muscle bleed | ~40–60% | Repeat dosing based on symptoms and measured levels. |
| Major bleed (deep muscle/CNS risk/high-impact trauma) | ~60–100% | Urgent treatment and close monitoring required. |
| Major surgery | Often ~80–100% perioperatively | Maintain troughs post-op per institutional protocol. |
Target ranges differ by guideline, product characteristics, and patient-specific risk. Always follow treating team protocol.
Example 1: 70 kg adult, current FIX 1%, target 50%, recovery 1.0
Desired rise = 50 − 1 = 49%
Dose = 70 × 49 ÷ 1.0 = 3430 IU
If using 500 IU vial increments, rounded dose ≈ 3500 IU.
Example 2: 25 kg child, current FIX 2%, target 40%, recovery 0.9
Desired rise = 40 − 2 = 38%
Dose = 25 × 38 ÷ 0.9 = 1055.6 IU
Rounded to 250 IU increments: ~1000 or 1250 IU depending on protocol and clinical urgency.
Bolus calculation gives an initial estimate, not a final guarantee of therapeutic level. Clinical practice improves accuracy by checking FIX activity after infusion and at planned trough points. This is especially important during surgery, severe bleeding, or when using less familiar products.
After an initial dose, subsequent dosing is usually guided by:
For routine planning, dose estimates should be paired with laboratory confirmation and clinical reassessment.
Children may show different PK behavior than adults and can require individualized dosing intervals. Frequent monitoring is often needed in acute care and perioperative settings.
Some centers use adjusted approaches in obesity for selected products or clinical contexts. Local protocol determines whether actual, ideal, or adjusted body weight is used.
Extended half-life concentrates can alter interval planning and maintenance strategy. Recovery and time-course assumptions should align with the specific product information and center protocol.
Suspected inhibitor presence, poor expected response, or discordant lab/clinical results require specialist management. Standard dose formulas may not apply reliably in these settings.
Safety note: This page is for education and planning support only. It does not provide individualized medical advice or replace urgent clinical care. For active bleeding, trauma, or perioperative management, contact a hemophilia treatment center immediately.
Choose targets based on bleed severity, location, procedure type, and institutional guideline. Mild events may use lower targets, while severe bleeding and major surgery often require higher initial targets and tighter trough maintenance.
If individualized PK data are unavailable, use your local protocol default for the specific product. A value near 1.0 IU/dL per IU/kg is commonly used for many standard settings, but this is not universal.
Yes, many centers round to available vial strengths for practicality and waste reduction, while balancing safety and target achievement.
Usually no. Initial bolus estimation is followed by reassessment, measured levels, and possible dose/interval adjustment until clinical goals are met.